表达于大肠杆菌中的人源性抗CTLA4单链抗体复性方法探索

探索表达于大肠杆菌中的人源性抗CTLA4单链抗体(Anti-CTLA4-scFv)的体外复性方法。采用稀释和透析两种复性方式,并分析影响复性得率的各种因素如复性时间、温度、适宜的氧化-还原体系对其的影响。通过非还原电泳确定复性效果,并测定蛋白含量。结果显示:含0.15mol·L-1NaCl、1μmol·L-1氧化型谷胱甘肽和3μmol·L-1还原型谷胱甘肽的50mmol·L-1Tris-HCl(pH8.0)缓冲液作为Anti-CTLA4-scFv的复性液,4℃下透析复性48~54h,可获得具有天然构象的蛋白质。该方法复性蛋白得率高,从3.9g菌体中可复性获得28mg蛋白。     

乙脑病毒鼠源单链抗体的构建及表达

目的 获得乙脑病毒（ＪＥＶ）鼠源单链抗体基因（ＳｃＦｖ）并使其在Ｅ．ｃｏｌｉ中表达。方法 利用噬菌体表面呈现技术,从抗乙脑病毒杂交瘤细胞２Ｈ４中构建噬菌体抗体库,采用双抗体夹心模式对抗体库进行富集及检测。并将所获得的阳性克隆重基因插入ＧＳＴ融合表达载体中,构建融合表达克隆重,使其在Ｅ．ｃｏｌｉ中获得稳定表达产物。结果 所构建的噬菌体抗体库经３轮的吸附、洗脱及再感染的富集过程后,共检测到７株稳定的具     

乙肝病毒核心蛋白人源单链抗体在大肠杆菌中的表达

目的 获得可溶性的抗乙型肝炎病毒（HBV）核心蛋白（core)的人源单链可变区抗体（ScFv)，为得到纯度高、活力强的HBc-ScFv和进一步的抗HBV治疗奠定基础。方法 采用噬菌体表面展示技术，以重组的HBV核心蛋白为包被抗原，从噬菌体单链可变区抗体库中经过5轮“吸附－洗脱－扩增”筛选过程，获得抗原结合活性较强的乙型肝炎核心蛋白人源单链可变区抗体ScFv片段克隆，并对其进行DNA序列及免疫活性测定。从噬菌体抗体阳性克隆中提取质粒转化大肠杆菌HB2151，IPTG诱导表达乙型肝炎核心蛋白可溶性人源单链可变区抗体，ELISA和western blot检测其抗原结合特异性。结果 克隆了乙型肝炎核心蛋白的单链可变区抗体基因；经DNA酶切和序列分析表明，该抗体基因由771个碱基组成；ELISA和western blot结果表明：在大肠杆菌HB2151中经IPTG诱导表达的可溶性乙型肝炎核心蛋白的单链可变区抗体，具有结合乙型肝炎核心蛋白的特异性和免疫活性。结论 克隆、鉴定并在大肠杆菌HB2151中表达了可溶性的HBc-ScFv。     

人源性抗HBsAg单链Fab基因在酵母中的表达

抗乙肝表面抗原的人源性抗体(Fab)在临床上有防治乙型肝炎病毒的应用前景，如用于预防新生儿乙型肝炎病毒的垂直传播和治疗性乙肝制剂等。本文将噬菌体抗体库筛选得到的人源性抗HBsAg Fab抗体基因，通过重叠PCR的方法借Linker将Fab的轻链(L链)和重链(H链)融合构建单一的链，即单链Fab(Single chain Fab)基因，并插入到酵母表达载体pPICZaA中。     

大肠杆菌表达的人源性抗CTLA4单链抗体三种复性方法比较

比较表达于大肠杆菌中的人源性抗细胞毒性T淋巴细胞抗原4单链抗体(A n ti-CTLA 4 scFv)的三种体外复性方法的复性效率。稀释、透析和亲和柱上三种复性方式复性A n ti-CTLA 4 scFv,采用B rad ford法分析蛋白复性得率,采用间接细胞EL ISA法检测所得蛋白的活性。透析复性蛋白得率最高,稀释复性蛋白得率其次,亲和柱上复性蛋白得率最低;透析复性所得蛋白结合活性是稀释复性的1.95倍,是亲和柱上复性所得蛋白活性的4.13倍(无谷胱甘肽氧化还原对G SH/G SSH)及3.63倍(有G SH/G SSH)。结论:采用含0.15 m o l/L N aC、l1 mm o l/L G SSH和3 mm o l/L G SH的50 mm o l/L T ris-HC l(pH 8.0)缓冲液作为A n ti-CTLA 4 scFv的复性液,4℃下透析复性48 h,可获得较高复性得率和结合活性。     

抗乙肝病毒表面抗原单链抗体在大肠杆菌中的高效表达

在大肠杆菌中高效表达抗乙肝表面抗原的单链抗体。方法：通过ＰＣＲ将单链抗体基因重组到原核细胞表达载体ＰＴ１７中,构建单链抗体高效表达载体ＰＴ７ＳＣ。将ＰＴ７ＳＣ质粒转化大肠杆菌ＢＬ２１,ＴＰＴＧ诱导进行表达。     

噬菌体表面呈现抗人红细胞血型A抗原单链抗体的研究

目的 构建表达抗人红细胞血型Ａ抗原５０Ａ杂交瘤细胞的单链抗体（ＳｃＦｖ）。方法 应用重组噬菌体抗体技术,从５０Ａ杂交瘤细胞中分离、构建单链抗体基因,并将其克隆入噬粒ｐＣＡＴＮＡＢ５Ｅ中,转化Ｅ．ｃｏｌｉ ＸＬ－Ｂｌｕｅ,辅助噬菌体援救构建５０Ａ噬菌体单链抗体库;采用完整红细胞亲和富集法淘选阳性重组噬菌体,鉴定重组噬菌体并进行序列测定分析;免疫印迹试验检测重组单链抗体的特异性抗原活性。结果 用Ｍ１３     

HBsAg人源噬菌体单链抗体的筛选及其在临床诊断中的应用

目的 筛选乙型肝炎病毒(HBV)表面抗原(HBsAg)的人源噬菌体单链抗体，并探讨其在临床治疗和诊断中的应用价值。方法 以HBsAg阳性血清超速离心纯化的HBsAg为固相抗原，从噬菌体单链可变区半合成抗体库中经过5轮“吸附—洗脱—扩增”筛选过程，获得特异性较强的HBsAg人源单链可变区抗体(ScFv)；用该抗体对10例石蜡包埋的乙型肝炎患者肝组织进行免疫组化鉴定。结果 酶联免疫吸附法(ELISA)结果表明，制备的HBV人源单链抗体能与HBsAg抗原特异性结合；免疫组化结果表明，该抗体能够特异性识别乙型肝炎患者肝组织中的HBsAg抗原，与正常肝组织及丙型肝炎病毒(HCV)的抗原均无交叉反应。结论 此法制备的单链抗体亲和性好，特异性强，且制备方法简便，周期短，为HBV病原的检测提供了新的有效试剂，为今后HBsAg人源抗体的研究和应用奠定了基础。     

人源化抗CD3单链抗体在大肠杆菌中的表达

在以前的工作中 ,我们利用本研究室制备的抗胶质瘤单克隆抗体ＳＺ39通过化学偶联的方法制备了抗ＣＤ3/抗胶质瘤双特异性抗体 ,并在体外细胞毒及荷瘤动物体内试验中取得较好疗效[1,2 ] ,但存在着分子量大 ,穿透力弱 ,免疫原性强 ,制备困难等缺点。因此 ,研制小分子 ,低免疫原性的人源化抗ＣＤ3/抗胶质瘤双特异性抗体是我们正在开展的研究项目之一。目前我们已构建并原核表达了抗胶质瘤单链抗体ＳＺ39 ＳｃＦｖ。本研究构建并表达的人源化抗ＣＤ3单链抗体 ,旨在为下一步制备高效低毒的抗ＣＤ3/抗胶质瘤双特异性抗体提供一个理想的构件。1　材…     

全人源性肝癌单链抗体的表达、纯化及功能鉴定

目的:在大肠杆菌中表达人源性肝癌单链抗体(scFv),并分析他的结合活性。方法:应用噬菌体表面呈现技术获得人源性肝癌scFv,利用重叠延伸PCR将VL和VH基因以(Gly4ser)3linker连接成单链,插入表达载体pET28a( ),诱导目的蛋白表达,对包涵体进行溶解、复性、纯化,得到可溶性目的蛋白,应用非竞争细胞ELISA检测与肝癌细胞结合的特异性及结合能力。结果:在A600为0.8时开始诱导,持续6h,目的蛋白表达量占菌体总蛋白的26%,包涵体经过复性纯化后,得到纯度达到95%的重组scFv,其亲和常数为:3.6×107mol/L。结论:实现了人源性肝癌scFv的蛋白表达,抗体蛋白与肝癌细胞具有较强的特异性结合能力,为今后进行免疫学检测和开发肿瘤靶向治疗提供了研究手段。     

Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments

Enhanced expression of epidermal growth factor receptor (EGFR) occurs on a variety of malignant tissues thus making anti-EGFR antibodies possible agents for the diagnosis and therapy of human tumors. Standard hybridoma technology has been used successfully to isolate anti-EGFR antibodies from immunized mice and rats. This report demonstrates that phage-antibody libraries are an alternative, and more versatile, method for isolating antibodies from immunized mice. Anti-EGFR antibodies were isolated from phage-antibody libraries constructed not only from the spleen of an immunized mouse but also from the draining lymph node of an immunized mouse and from in vitro immunized mouse cells. Two of the single-chain Fv isolated from the phage-antibody libraries were engineered to create partially humanized whole antibody molecules.     

重组人G—CSF免疫小鼠全套单链抗体噬菌体表面展示文库的构建

利用全套噬菌体抗体表面展示技术,绕过杂交瘤技术,从重组人G-CSF免疫的小鼠脾淋巴细胞中提取总RNA,反转录成cDNA后,用抗体可变区PCR混合引物进行全套抗体重、轻链可变区（VH和VL）基因的扩增。经重叠延伸反应,在体外随机装配成单链抗体（ScFv）。将其克隆至噬菌粒载体pCANTAB5E中,电转化含SupE的E.Coli菌株,以辅助噬菌体M13K07超感染噬菌粒文库,构建成全套ScFv表面展示文库。为利用亲和富集筛选技术,获得具有G-CSF结合活性的完整重组噬菌粒克隆奠定了基础。     

抗HBsAg/RBC双特异噬菌体抗体的构建

目的 通过不同外壳蛋白的展示，构建抗HBsAag/RBC双特异噬菌体抗体。方法通过DNA重组技术，将抗HBsAg Fab与噬菌体基因8融合，抗RBC ScFv与噬菌体基因3融合，这2种融合基因以不同的启动子驱动，并克隆于同一噬菌体表达载体上，得到双特异噬菌体抗体表达载体，转化大肠杆菌后获取噬菌体抗体上清，用ELISA和红细胞凝集试验检测其双特异活性。结果ELISA和RBC凝集实验证明，本方法可形成双特异噬菌体抗体，可使含有HBsAg的RBC悬液产生凝集。用展示性能得到提高的蛋白8变种取代野生型蛋白8可提高双特异噬菌体抗体的活性。结论 HBsAb和RBC两种抗体分子能够通过不同噬菌体外壳蛋白同时展示于同一噬菌体表面，形成双特异噬菌体抗体。可用于人外周血HBsAg的快速血凝法检测。     

Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection

Several antibody-dependent mechanisms have been postulated to mediate neutralization of different animal viruses, including blocking of docking to receptors, induction of conformational changes in the virus coat, and Fc-dependent opsonization. We have studied the molecular requirements for antibody-mediated neutralization of vesicular stomatitis virus (VSV) in vitro and protection against lethal disease in vivo with a single-chain Fv fragment (scFv) and the corresponding bivalent miniantibody (scFv-dHLX) generated from a VSV-neutralizing monoclonal antibody. Both monovalent scFv and bivalent scFv-dHLX miniantibodies were able to neutralize VSV in vitro and to protect interferon-αβ receptor-deficient (IFN-αβR^−/−) mice against lethal disease after intravenous injection of 50 plaque-forming units (pfu) VSV pre-incubated with the scFv reagents. Similarly, severe-combined immunodeficient (SCID) mice infected with immune complexes of 10⁸ pfu VSV and bivalent scFv-dHLX were protected against lethal disease; however, mice infected with immune complexes of 10⁸ pfu VSV and monovalent scFv were not. Although repeated scFv-dHLX treatment reduced virus quantities in the blood, neither SCID nor IFN-αβR^−/− mice were protected against lethal disease after passive immunization and subsequent VSV infection. This was due to the short half-life of 17 min of scFv-dHLX in the circulation. These data demonstrate that neutralization of VSV and protection against lethal disease do not require Fc-mediated mechanisms and that cross-linking is not crucial for protection against physiologically relevant virus doses in vivo.     

Selection of Rabbit Single-chain Fv Fragments against the Herbicide Atrazine using a New Phage Display System

A convenient new bacteriophage display vector, pSD3, has been constructed and used to generate rabbit monoclonal anti-pesticide antibody fragments. Following amplification of immunoglobulin light chain, and heavy chain variable region gene libraries, restriction enzymes Sfi I and PflM I are used to assemble scFv libraries in pSD3. This allows the number of stages involving the polymerase chain reaction and restriction enzyme digestion to be minimized to optimize maintenance of the original diversity of the variable region genes in the libraries. The vector also incorporates an amber codon, a 6xHis tag and a c-myc epitope to facilitate soluble single-chain Fv production detection and purification. Using the pSD3 system two anti-atrazine single-chain Fvs were isolated from a library derived from the spleen cells of a rabbit immunized with bovine serum albumin-atrazine conjugate. Characterization of single-chain Fvs by competition and equilibrium ELISA indicated good specificity and affinity to atrazine.     

Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies

Monoclonal antibodies (mAb) against the main immunogenic region (MIR) of the acetylcholine receptor (AChR) are very potent in inducing antigenic modulation of the AChR in animals and in muscle cell cultures. A recombinant antibody fragment of the rat anti-MIR mAb198 was cloned by polymerase chain reaction and expressed as soluble single-chain Fv fragment (scFv198) in E. coli and affinity purified. DNA sequencing was used to define the VH (IB) and VL (K2) chain gene usage. scFv198 was found immunologically and biologically active. Its binding affinity for the Torpedo AChR (K_D=2 ± 0.6 nM) was very similar with that of the intact mAb198 (K_D=1.8 ± 0.6 nM) while for the human AChR(K_D=80.7 ± 16.6 nM) it was about four times lower than that of the intact mAb198 (K_D=21.6 ± 6.6 nM). This fragment was capable of efficiently protecting the AChR in human cell cultures, against antigenic modulation caused by the intact mAb198 or by the antibodies from a myasthenic patient. The produced scFv198 fragment is, therefore, potentially useful in therapeutic applications for myasthenia gravis after appropriate genetic manipulations.     

抗人DR5单链抗体噬菌体展示文库的建立和筛选

目的应用噬菌体展示技术构建抗人DR5(death receptor 5,DR5)单链抗体(single chain Fv,scFv)文库,从中筛选抗DR5 scFv。方法利用重组人DR5抗原免疫小鼠,分别扩增小鼠VH和VL基因,经重叠延伸PCR将VH和VL基因拼接成scFv基因,以SfiⅠ位点定向插入PAK100噬菌粒载体,转化E.coli XL1-Blue,构建了库容为1×106的抗DR5单链抗体库。对抗体库进行5轮富集筛选后,phage-ELISA检测阳性克隆的抗原特异性,取1株阳性克隆进行测序分析。结果抗DR5 scFv基因序列长747 bp,编码249个氨基酸,具有和DR5结合的特异性。结论本文利用噬菌体抗体库筛选到了抗DR5 scFv,为研制临床免疫治疗的新型抗体奠定了实验基础。     

去唾液酸糖蛋白受体特异性单链抗体的优化表达及亲和常数的测定

目的:表达及纯化抗去唾液酸糖蛋白受体(ASG-PR)的单链抗体的可溶性,并测定其亲和常数。方法:用噬菌体C1克隆感染E.coliHB2151,挑取单个菌落接种于2×TY培养基中,于37℃震荡培养过夜。将培养物作1∶100稀释并转种后,用终浓度为0.25、0.5、1.0mmol/L的IPTG,分别在37℃、25℃和20℃下诱导表达过夜。取其培养上清,用饱和硫酸铵沉淀后,以120g/LSDS-PAGE分析。另外,将饱和硫酸铵沉淀物用30mLPBS重新溶解、透析除盐后,用Ni2 螯合柱进行纯化,再以120g/LSDS-PAGE鉴定纯化scFvC1的纯度。用非竞争酶免疫法测定scFv的亲和常数。结果:用0.5mmol/LIPTG在25℃诱导过夜,表达的scFvC1的量较多,其相对分子质量(Mr)约为28000,以可溶性的形式存在于培养基中。通过Ni2 亲和柱纯化后scFvC1的纯度在95%以上,产量约为0.8mg/L。scFv的亲和常数为(2.31±0.36)×10-7mol/L。结论:以筛选的C1噬菌体感染E.coliHB2151后可表达低亲和力的可溶性scFv,对肝癌的基因治疗具有潜在的应用价值。     

Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron

A large human nonimmune phage antibody library was screened by affinity chromatography to select single-chain antibodies directed against the human receptor tyrosine kinase (RTK) Ron. As antigen, we used a GST fusion protein (GST-IRP(-)) containing the whole intracellular portion of Ron except for the carboxyl-terminal arginine-proline-rich motif. One selected phage was highly specific for Ron when tested in an enzyme-linked immunosorbent assay (ELISA). We report here the immunological characterization of this anti-Ron single-chain antibody (sc7) and show that it recognizes both denatured and native forms of the receptor. The epitope bound by sc7 maps within the first 50 amino acid residues of the juxtamembrane domain of Ron. This monoclonal fragment does not cross-react with other receptor tyrosine kinases including the closely related human proto-oncogene Met. We demonstrate that the isolated antibody fragment interacts in vivo with the intracellular domain of Ron in mammalian cells.